Galmed Pharmaceuticals announced the grant of a European patent related to the use of a combination of Aramchol and Resmetirom for the treatment of NASH/MASH and liver fibrosis. The patent was granted in France, Germany, Italy, the Netherlands and the United Kingdom and the approval of the patent in the United States and other countries is pending. With this latest patent, Galmed is strengthening and extending the patent protection of its lead compound, Aramchol, until September 2039.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
